No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
JBM HEALTHCARE: 2024/2025 Interim Report
Hong Kong stock market anomaly | jbm healthcare (02161) rose more than 14%, hitting a new high in nearly three and a half years. Mid-term net profit increased by more than fifty percent year-on-year.
jbm healthcare (02161) rose more than 14%, reaching a high of 1.62 Hong Kong dollars, hitting a new high since June 2021. As of the time of publication, it increased by 14.89%, closing at 1.62 Hong Kong dollars, with a turnover of 9.4191 million Hong Kong dollars.
JBM (Healthcare)'s Profit Zooms 53% in Fiscal H1
jbm healthcare (02161.HK) reported a mid-term profit attributable to equity holders of 95.9 million Hong Kong dollars, an increase of approximately 53.4% year-on-year.
Grondlohui, November 19th, jbm healthcare (02161.HK) announced that the profit for the six months ended September 30, 2024, was approximately 0.399 billion Hong Kong dollars, an increase of about 22.1% compared to the same period in 2023. During the same period, the company's equity holders' share of profit was approximately 95.9 million Hong Kong dollars, an increase of about 53.4% compared to the same period in 2023. The board of directors declared an interim dividend of HK$5.50 per ordinary share for the six months ended September 30, 2024 (total amount about 45.2 million Hong Kong dollars), an increase of about 59.4% compared to HK$3.45 per ordinary share in the same period in 2023. Brand traditional chinese medicine division.
No Data
